KIR gene mismatching and KIR/C ligands in liver transplantation: Consequences for short-term liver allograft injury

Transplantation

Volumn 95, Issue 8, 2013, Pages 1037-1044

  Legaz, Isabel ^a   López Álvarez, María R ^a   Campillo, José A ^a   Moya Quiles, María R ^a   Bolarín, José M ^a   De La Peña, Jesus ^a   Salgado, Gema ^a   Gimeno, Lourdes ^a   García Alonso, Ana M ^a   Muro, Manuel ^a   Miras, Manuel ^a   Alonso, Clara ^b   Álvarez López, María R ^a   Minguela, Alfredo ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

^b HOSPITAL JUAN CANALEJO   (Spain)

Author keywords

Acute rejection; HLA ligands; KIR; Liver transplantation; Short term graft survival

Indexed keywords

HLA ANTIGEN CLASS 1; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; LIGAND;

ADULT; ALLOIMMUNITY; ARTICLE; CONTROLLED STUDY; FEMALE; GENOTYPE; GRAFT RECIPIENT; GRAFT SURVIVAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MALE; NATURAL KILLER CELL; ORGAN DONOR; PRIORITY JOURNAL; T LYMPHOCYTE;

COHORT STUDIES; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HEPATITIS C; HISTOCOMPATIBILITY TESTING; HLA-C ANTIGENS; HUMANS; KILLER CELLS, NATURAL; LIGANDS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; RECEPTORS, KIR; RECEPTORS, KIR2DL3; RECURRENCE; T-LYMPHOCYTE SUBSETS; TIME FACTORS;

EID: 84876682404     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e318286486c     Document Type: Article

References (70)

1. Kärre K, Ljunggren HG, Piontek G, et al. Selective rejection of H-2 deficient lymphoma variants suggests alternative immune defence strategy. Nature 1986; 319: 675.
2. Ljunggren HG, Karre K. In search of the "missing self": MHC molecules and NK cell recognition. Immunol Today 1990; 11: 237.
3. Wu J, Lanier LL. Natural killer cells and cancer. Adv Cancer Res 2003; 90: 127
4. French AR, Yokoyama WM. Natural killer cells and viral infections. Curr Opin Immunol 2003; 15: 45.
5. Lanier LL. NK cell receptors. Annu Rev Immunol 2005; 23: 225.
6. Michael JW, Torkar M, Haude A, et al. Plasticity in the organization and sequences of human KIR/ILT gene families. Proc Natl Acad Sci U S A 2000; 97: 4778.
7. Moretta L, Moretta A. Killer immunoglobulin-like receptors. Curr Opin Immunol 2004; 16: 626.
8. Parham P. Immunogenetics of killer cell immunoglobulin-like receptors. Mol Immunol 2005; 42: 459.
9. Moretta A, Sivori S, Vitale M, et al. Existence of both inhibitory (p58) and activatory (p50) receptors for HLA-C molecules in human natural killer cells. J Exp Med 1995; 182: 875.
10. Colonna M, Samaridis J. Cloning of immunoglobulin-superfamily members associated with HLA-C and HLA-B recognition by human natural killer cells. Science 1995; 268: 405.
11. Gumperz JE, Litwin V, Phillips JH, et al. The Bw4 public epitope of HLA-B confers reactivity with natural killer cell clones that express NB1, a putative HLA receptor. J Exp Med 1995; 181: 113.
12. Stewart CA, Laugier-Anfossi F, Vély F, et al. Recognition of peptide-MHC class I complexes by activating killer immunoglobulin-like receptors. Proc Natl Acad Sci U S A 2005; 102: 13224.
13. Chewning JH, Gudme CN, Hsu KC, et al. KIR2DS1-positive NK cells mediate alloresponse against the C2 HLA-KIR ligand group in vitro. J Immunol 2007; 179: 854.
14. Foley B, De Santis D, Lathbury L, et al. KIR2DS1-mediated activation overrides NKG2A-mediated inhibition in HLA-C C2-negative individuals. Int Immunol 2008; 20: 555.
15. Katz G, Markle G, Mizhari S, et al. Recognition of HLA-Cw4 and HLA-Cw6 by the NK cell killer cell Ig-like receptors NK cell receptor two domain short tail number 4. J Immunol 2001; 166: 7260.
16. Graef T, Moesta AK, Norman PJ, et al. KIR2DS4 is a product of gene conversion with KIR3DL2 that introduced specificity for HLA-A*11 while diminishing avidity for HLA-C. J Exp Med 2009: 206:2557.
17. Merino A, Malhotra R, Mulenga J, et al. Impact of a functional KIR2DS4 allele on heterosexual HIV-1 transmission among discordant Zambian couples. J Infect Dis 2011; 203: 487.
18. Ruggeri L, Capanni M, Urbani E, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002: 295:2097.
19. Velardi A, Ruggeri L, Moretta A, et al. NK cells: a lesson from mismatched hematopoietic transplantation. Trends Immunol 2002; 23: 438.
20. Cook MA, Milligan DW, Fegan CD, et al. The impact of donor KIR and patient HLA-C genotypes on outcome following HLA-identical sibling hematopoietic stem cell transplantation for myeloid leukemia. Blood 2004; 103: 1521.
21. Ruggeri L, Mancusi A, Burchielli E, et al. NK cell alloreactivity and allogeneic hematopoietic stem cell transplantation. Blood Cells Mol Dis 2008; 40: 84.
22. Moretta L, Locatelli F, Pende D, et al. Human NK receptors: from the molecules to the therapy of high risk leukemias. FEBS Let 2011; 585: 1563.
23. Zhao XY, Huang XJ, Liu K, et al. Prognosis after unmanipulated HLA-haploidentical blood and marrow transplantation is correlated to the numbers of KIR ligands in recipients. Eur J Haematol 2007; 78: 338.
24. Symons JH, Lefell MS, Rossiter N, et al. Improved survival with inhibitory killer immunoglobulin receptor (KIR) gene mismatches and KIR haplotype B donors after nonmyeloablative HLA-haploidentical bone marrow. Biol Blood Marrow Transplant 2010; 16: 533.
25. Schellekens J, Rozemuller EH, Peterson EJ, et al. Activating KIRs exert a role on relapse and overall survival after HLA-identical sibling transplantation. Mol Immunol 2008; 45: 2255.
26. Giebel S, Nowak I, Dziaczkowska J, et al. Activating killer immunoglobulin-like receptor incompatibilities enhance graft-versus-host disease and affect survival after allogenic haematopoietic stem cell transplantation. Eur J Haematol 2009; 83: 343.
27. Chen DF, Prasad VK, Broadwater G, et al. Differential impact of inhibitory and activating killer Ig-like receptors (KIR) on high-risk patients with myeloid and lymphoid malignancies undergoing reduced intensity transplantation from haploidentical related donors. Bone Marrow Transplant 2012; 47: 817.
28. Maier S, Tertilt C, Cambron N, et al. Inhibition of natural killer cells results in acceptance of cardiac allografts in CD28j/j mice. Nat Med 2001; 7: 557.
29. Uehara S, Chase CM, Kitchens WH, et al. NK cells can trigger allograft vasculopathy: the role of hybrid resistance in solid organ allografts. J Immunol 2005; 175: 3424.
30. van Bergen J, Thompson A, Haasnoot GW, et al. KIR-ligand mismatches are associated with reduced long-term graft survival in HLA-compatible kidney transplantation. Am J Tranplant 2010; 11: 959.
31. Rajalingam R. Variable interactions of recipient killer cell immunoglobulin-like receptors with self and allogenic human leukocyte antigen class I ligands may influence the outcome of solid organ transplants. Curr Opin Organ Transplant 2008; 13: 43.
32. Villard J. The role of natural killer cells in human solid organ and tissue transplantation. J Innate Immun 2011; 3: 395.
33. Moya-Quiles MR, Muro M, Torío A, et al. Human leukocyte antigen-C in short and long-term liver graft acceptance. Liver Transpl 2003; 9: 218.
34. Bishara A, Brautbar C, Zamir G, et al. Impact of HLA-C and Bw epitopes disparity on liver transplantation outcome. Hum Immunol 2005; 66: 1099.
35. Moya-Quiles MR, Alvarez R, Miras M, et al. Impact of recipient HLA-C in liver transplant: a protective effect of HLA-Cw*07 on acute rejection. Hum Immunol 2007; 68: 51.
36. Ló pez-Alvarez MR, Moya-Quiles MR, Minguela A, et al. HLA-C matching and liver transplants: donor-recipient genotypes influence early outcome and CD8+KIR2D+ T-cells recuperation. Transplantation 2009; 88: S54.
37. Hanvesakul R, Spencer N, Cook M, et al. Donor HLA-C genotype has a profound impact on the clinical outcome following liver transplantation. Am J Transplant 2008; 8: 1931.
38. Tran TH, Middleton D, Döhler B, et al. Reassessing the impact of donor HLA-C genotype on long-term liver transplant survival. Am J Transplant 2009; 9: 1674.
39. Moroso V, van der Meer A, Tilanus HW, et al. Donor and recipient HLA/KIR genotypes do not predict liver transplantation outcome. Transpl Int 2011; 24: 932.
40. Espadas de Arias A, Haworth SE, Belli L, et al. Killer cell immunoglobulin-like receptor genotype and killer cell immunoglobulin-like receptorY human leukocyte antigen C ligand compatibility affect the severity of hepatitis C virus recurrence after liver transplantation. Liver Transpl 2009; 15: 390.
41. Crispe IN. Hepatic T cells and liver tolerance. Nat Rev Immunol 2003; 3: 51.
42. Moroso V, Famili F, Papazian N, et al. NK cells can generate from precursors in the adult human liver. Eur J Immunol 2011; 41: 3340.
43. Kohler S, Pascher A, Junge G, et al. Graft versus host disease after liver transplantationVa single center experience and review of literature. Transpl Int 2008; 21: 441.
44. Ayala R, Grande S, Albizua E, et al. Long-term follow-up of donor chimerism and tolerance after human liver transplantation. Liver Transpl 2009; 15: 581.
45. Khakoo SI, Thio CL, Martin MP, et al. HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science 2004; 305: 872.
46. Knapp S, Warshow U, Hegazy D, et al. Consistent beneficial effect of killer immunoglobulin-like receptor 2DL3 and group 1 human leukocyte antigenYC following exposure to hepatitis C virus. Hepatology 2010; 51: 1168.
47. López-Alvarez MR, Campillo JA, Legaz I, et al. Divergences in KIR2D+ natural killer and KIR2D+CD8+ T-cell reconstitution following liver transplantation. Hum Immunol 2011; 72: 229.
48. Gagne K, Busson ML, Balere-Appert L, et al. Relevance of KIR gene matching in unrelated haematopoietic stem cell transplantations. Tissue Antigens 2007; 69: 118.
49. MacQueen KL, Dorighi KM, Guethlein LA, et al. Donor recipients combinations of group A and B KIR haplotypes and HLA class I ligands affect the outcome of HLA-matched, sibling donor hematopoietic cell transplantation. Hum Immunol 2007; 68: 309.
50. + NK cells in haploidentical stem cell transplantation. J Leukoc Biol 2011; 90: 661.
51. Nowak I, Majorczyk E, Wisniewiski A, et al. Does KIR2DS5 gene protect from some human disease? PLoS One 2010; 5: e12381.
52. Jamil KM, Khakoo SI. KIR/HLA interactions and pathogen immunity. J Biomed Biotech 2011; 2011: 298348.
53. Bonagura VR, Du Z, Ashouri E, et al. Activating killer cell immunoglobulin-like receptors 3DS1 and 2DS1 protect against developing the severe form of recurrent respiratory papillomatosis, Hum Immunol 2010; 71: 212.
54. Körner C, Altfeld M. Role of KIR3DS1 in human diseases. Front Immunol 2012; 3: 326.
55. Parham P. MHC class I molecules and KIRs in human history, health and survival. Nat Rev Immunol 2005; 5: 201.
56. Chazara O, Xiong S, Moffet A. Maternal and fetal HLA-C: a fine balance. J Leukoc Biol 2011; 90: 703.
57. Kulkarni S, Martin MP, Carrington M. The Yin and Yang of HLA and KIR in human disease. Semin Immunol 2008; 20: 343.
58. Bari R, Bell T, Leung WH, et al. Significant functional heterogeneity among KIR2DL1 alleles and pivotal role of arginine 245. Blood 2009; 114: 5182.
59. Moesta AK, Norman PJ, Yawata M, et al. Synergistic polymorphismattwo positions distal to the ligand-binding site makes KIR2DL2 a stronger receptor for HLA-C than KIR2DL3. J Immunol 2008; 180: 3669.
60. Schönberg K, Sribar M, Enczmann J, et al. Analyses of HLA-CYspecific KIR repertoires in donors with group A and B haplotypes suggest a ligand-instructed model of NK cell receptor acquisition. Blood 2011; 117: 98.
61. Vilches C, Parham P. KIR: diverse, rapidly evolving receptors of innate and adaptive immunity. Annu Rev Immunol 2002; 20: 217.
62. Crum KA, Logue SE, Curran MD, et al. Development of a PCR-SSOP approach capable of defining the natural killer cell inhibitory receptor (KIR) gene sequence repertoires. Tissue Antigens 2000; 56: 313.
63. Norman PJ, Stephens HA, Verity DH, et al. Distribution of natural killer cell immunoglobulin-like receptor sequences in three ethnic groups. Immunogenetics 2001; 52: 195.
64. Husain Z, Alper CA, Yunis EJ, et al. Complex expression of natural killer receptor genes in single natural killer cells. Immunology 2002; 106: 373.
65. Pende D, Marcenaro S, Falco M, et al. Anti-leukemia activity of alloreactive NK cells in KIR ligandYmismatched haploidentical HSCT for pediatric patients: evaluation of the functional role of activating KIR and redefinition of inhibitory KIR specificity. Blood 2009; 113: 3119.
66. Vidal-Castiñeira JR, Lopez-Vazquez A, Diaz-Peña R, et al. Effect of killer immunoglobulin-like receptors in the response to combined treatment in patients with chronic hepatitis C virus infection. J Virol 2010; 84: 475.
67. Askar M, Avery R, Corey R, et al. Lack of killer immunoglobulin-like receptor 2DS2 (KIR2DS2) and KIR2DL2 is associated with poor responses to therapy of recurrent hepatitis C virus in liver transplantation. Liver Transpl 2009; 15: 1557.
68. Seich al Batasena NK, MacNamara A, Vine AM, et al. KIR2DL2 enhance protective an detrimental HLA class I-mediated immunity in chronic infection. PLoS Pathog 2011; 7: e1002270.
69. Katz G, Gazit R, Arnon TI, Gonen-Gross T, et al. MHC class IYindependent recognition of NK-activating receptor KIR2DS4. J Immunol 2004; 173: 1819.
70. Bao XJ, Hou LH, Sun AN, et al. The impact of KIR2S4 alleles and expression of KIR in development of acute GVHD after unrelated alloge-neic haematopoietic SCT. Bone Marrow Transplant 2010; 45: 1435.